Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism
Matthias Hoke(Medical University of Vienna), Sabine Eichinger(Medical University of Vienna), Paul A. Kyrle(Karl Landsteiner Society), Christine Bialonzcyk(Wilhelminen Hospital), Barbara Schneider(Altonaer Kinderkrankenhaus), Erich Minar(Medical University of Vienna), Ansgar Weltermann, Mirko Hirschl(Hanusch Hospital), Marietta Kollars(Medical University of Vienna)
Cited by 68
Related Papers
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
|New England Journal of Medicine|2021|2.3k
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery
|New England Journal of Medicine|2006|1.2k
High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2000|765